Dr. Wang's academic interest focuses on biliary atresia. Biliary atresia is a disease of infants where the bile ducts are damaged due to unclear causes. As a consequence of the damage, bile is unable to flow from the liver and progressive liver damage occurs. Biliary atresia is the most common indication for pediatric liver transplantation. Dr. Wang is the Principal Investigator for an NIH funded U01 grant for CHLA focusing on biliary atresia and other liver diseases of infants and children. The grant enables CHLA to participate in the Childhood Liver Disease Research and Education Network (ChiLDREN) which is a consortium of 15 of the top children's hospitals in the U.S. and Canada joined to studies rare but lethal pediatric liver diseases. To date, nearly 1500 patients with biliary atresia have been enrolled in number studies and clinical trials through ChiLDREN. Currently enrollment in a prospective randomized double blinded placebo controlled study on the efficacy of corticosteroids in the treatment of patients with biliary atresia after Kasai portoenterostomy is closed. Unblinding of data will occur in 2013 to be followed by publication of observations. In addition to involvement in ChiLDREN, Dr. Wang heads a research program focusing on the molecular events involved in biliary atresia. His research lab focuses on the signaling pathways regulating liver stem/progenitor cells during liver organogenesis and a variety of liver damage such as that incurred by biliary atresia.